Breaking News

Kivu Bioscience, Sterling Pharma Solutions Enter Manufacturing Pact

Sterling will manufacture cGMP clinical material for KIVU-107 at its bioconjugation facility in Deeside, UK.

Kivu Bioscience, a biotech company developing next-gen antibody-drug conjugates (ADCs), entered a manufacturing agreement with Sterling Pharma Solutions, a global CDMO, to produce cGMP-quality material for Phase 1 clinical trials of its lead oncology ADC candidate, KIVU-107. Sterling will manufacture cGMP clinical material for KIVU-107 at its dedicated bioconjugation facility in Deeside, UK. The collaboration includes process familiarization, analytical development, process optimization, and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters